1 Noncompliance among persons assigned to be screened Especially in studies in which participants are not restricted to those who have expressed a willingness to allow chance to dictate their screening status, the degree of non-adherence to a screening intervention can be considerable. An intent-to-screen analysis inevitably will provide a watered-down estimate of any favorable impact of the intervention in those who actually receive it. As a means of overcoming this bias, some recent trials have compared the observed mortality from breast cancer (Moss et al., 2006) or colorectal cancer (Atkin et al., 2010) , for example, between screening compliers and the mortality expected among control participants who would have been screened had screening been offered to them. This expected mortality is estimated by: (a) documenting the proportion of noncompliers in the intervention arm of the trial, along with their cancer-specific mortality rate; and (b) subtracting from persons in the unscreened arm of the trial both the number of hypothetical noncompliers and the number of cancer deaths projected to have occurred in them.
2 Changes over time in the sensitivity of the screening modality or the efficacy of cancer treatment
Randomized trials of radiologic screening for lung cancer by means of chest X-ray did not observe a reduction in lung cancer mortality associated with screening (Marcus et al., 2000) . In contrast, later trials of radiologic screening by means of helical CT did observe such a reduction (The National Lung Screening 3 An evaluation of the efficacy of the screening intervention that is too short in duration
Screening is designed to identify cancers at an early stage of their natural history, and so the deaths that a successful screening measure can prevent typically are those that would occur no sooner than several years after the tumor (or a precursor lesion) has been screen-detected. Therefore, in a comparison of mortality from a given form of cancer between persons assigned and not assigned to be screened, for a period of time (perhaps several years or more) there would not be a difference between the groups, even for a highly effective screening measure (Hanley, 2010) . The absence of a mortality difference in the early years will dilute the estimate of the benefit that would be present in screenees in the longer term. For example, the estimated 15% reduction in prostate cancer mortality associated with PSA screening in the European Study of Screening for Prostate Cancer (Schroder et al., 2009 ) was based on an analysis in which the average duration of follow-up of participants was nine years. However, during the first seven years following the initiation of screening there was NO mortality reduction seen -many prostate cancers that ultimately prove fatal likely have a relatively long natural history. All of the mortality reduction that was observed in the trial was due to a considerably larger reduction beginning more than seven years from screening initiation. When the screening program and participant follow-up continued through 13 years, the mortality reduction (calculated across all years) grew to 21% (Schroder et al., 2014) .
Miettinen bemoans the relative dearth of involvement of epidemiological researchers in randomized trials of screening for cancer, implying (to me) that he believes that the planning of the design and analysis of future trials would do well to consider issues such as 1-3 above. I would add to this the recommendation that when seeking to estimate the benefits of recommending or providing screening to members of a given population, persons INTERPRETING the results of randomized trials of cancer screening (past and future) also would do well to consider these issues.
